Yourlawyer.com (Astellas Prograf Antitrust Lawsuit News) http://www.yourlawyer.com/topics/overview/Astellas-Prograf-Antitrust-Lawsuit-Illegal-Delay-Generic-Version Sun, 21 Sep 2014 02:03:45 -0400 Sun, 21 Sep 2014 02:03:45 -0400 pixel-app en Litigation over Alleged Astellas Prograf Monopoly Growing http://www.yourlawyer.com/articles/title/litigation-over-alleged-astellas-prograf-monopoly-growing Tue, 17 May 2011 00:00:00 -0400 http://www.yourlawyer.com/articles/title/litigation-over-alleged-astellas-prograf-monopoly-growing Antitrust litigation against Astellas Pharma Inc. over its handling of  the drug Prograf is growing.  So far, at least three Astellas Prograf antitrust lawsuits have been filed in federal courts in Massachusetts  and  Delaware, and  it seems more are expected.  The Judicial Panel on Multidistrict litigation is considering a motion requesting that all Astellas Prograf antitrust lawsuits be consolidated in a multidistrict litigation.

Prograf, which costs patients around $1,500 per month, is the brand name for tacrolimus.  It was approved in 1997, and is used to prevent organ rejection in transplant victims.

Antitrust lawsuits claim Astellas tried to hold on to its Prograf monopoly even after its exclusive patent expired by filing a “sham” petition with the U.S. Food and Drug Administration (FDA) in 2007.   The petition asked the FDA to establish more stringent standards for companies seeking approval of generic versions of tacrolimus.  When that didn't work, Astellas went to court to stop the FDA from approving a generic form of tacrolimus.  As a result, a cheaper generic version of the drug was not made available until 2009.

Astellas claimed its petition was filed in the interest of patient safety,  but plaintiffs in the Prograf antitrust lawsuits don't see it that way. Astellas was “keenly aware that it would lose a substantial amount of its sales of Prograf very quickly once AB-rated generics came to market," one complaint alleges.

Such  lawsuits further allege Astellas violated the Sherman Act by illegally maintaining a monopoly in the market for Prograf and charging supracompetitive prices for the drug. Because of this, the complaints claim Astellas was able  to overcharge purchasers of Prograf by millions of dollars.


]]>
Astellas Prograf Antitrust | Lawsuit, Lawyer | Illegal Delay Of Generic Version, Monopoly, Cheaper Generic Version http://www.yourlawyer.com/topics/overview/Astellas-Prograf-Antitrust-Lawsuit-Illegal-Delay-Generic-Version Tue, 17 May 2011 00:00:00 -0400 http://www.yourlawyer.com/topics/overview/Astellas-Prograf-Antitrust-Lawsuit-Illegal-Delay-Generic-Version Astellas Prograf Antitrust Lawsuit

Astellas Prograf Antitrust | Lawsuit, Lawyer | Illegal Delay Of Generic Version, Monopoly, Cheaper Generic Version

Our antitrust lawyers are investigating lawsuits against Astellas Pharma Inc. for illegally working to delay generic versions of the immune- suppressant medication Prograf (tacrolimus). Prograf is a drug used to prevent rejection in organ transplant patients. Astellas has been accused of filing a “sham” petition with the U.S. Food and Drug Administration (FDA) in order to keep cheaper, generic versions of Prograf off the market.

If you sustained economic damages because of Astellas' maneuvering to stop generic competition for Prograf, our antitrust lawyers want to hear from you. We are offering free legal consultations to anyone wishing to file an Astellas Prograf antitrust lawsuit. To find out how we can help you, please contact our antitrust lawyers today.

Astellas Prograf Monopoly

Prograf (tacrolimus capsules and injection) is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. The drug was first approved in 1997. Prograf is a pricey medication, and can cost as much as $1,500 per month.

Astellas filed a citizen petition in September 2007 asking the FDA to establish more stringent standards for companies seeking approval of generic versions of Prograf, including additional bioequivalence studies. The FDA rejected the petition, and Astellas sought a temporary restraining order and preliminary injunction in court to prevent the agency from approving a generic version of Prograf. In 2009, the U.S. District Court for the District of Columbia rejected Astellas' request.

Astellas Prograf antitrust lawsuits allege that the company's 2007 FDA petition was a "sham" that allowed it to maintain a monopoly on the market for tacrolimus for two years. Such lawsuits maintain that the only difference between generic versions of tacrolimus and Prograf is price. They further allege that Astellas was "keenly aware that it would lose a substantial amount of its sales of Prograf very quickly" once generic tacrolimus came to market. The delay in bringing generics to market allowed Astellas to overcharge purchasers of Prograf by millions of dollars, plaintiffs allege.

Legal Help for Victims of Astellas Prograf Monopoly

If you were a victim of Astellas' allegedly monopolistic behavior in regards to Prograf, you may have valuable legal rights. To discuss your case with one of our antitrust lawyers, please fill out our online form, or call 1-800-YOURLAWYER (1-800-968-7529) today.

]]>